These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11992787)

  • 1. Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives.
    Wyatt PG; Allen MJ; Chilcott J; Gardner CJ; Livermore DG; Mordaunt JE; Nerozzi F; Patel M; Perren MJ; Weingarten GG; Shabbir S; Woollard PM; Zhou P
    Bioorg Med Chem Lett; 2002 May; 12(10):1405-11. PubMed ID: 11992787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives.
    Wyatt PG; Allen MJ; Chilcott J; Foster A; Livermore DG; Mordaunt JE; Scicinski J; Woollard PM
    Bioorg Med Chem Lett; 2002 May; 12(10):1399-404. PubMed ID: 11992786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of GSK221149A: a potent and selective oxytocin antagonist.
    Liddle J; Allen MJ; Borthwick AD; Brooks DP; Davies DE; Edwards RM; Exall AM; Hamlett C; Irving WR; Mason AM; McCafferty GP; Nerozzi F; Peace S; Philp J; Pollard D; Pullen MA; Shabbir SS; Sollis SL; Westfall TD; Woollard PM; Wu C; Hickey DM
    Bioorg Med Chem Lett; 2008 Jan; 18(1):90-4. PubMed ID: 18032036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformationally constrained o-tolylpiperazine camphorsulfonamide oxytocin antagonists. Structural modifications that provide high receptor affinity and suggest a bioactive conformation.
    Williams PD; Ball RG; Clineschmidt BV; Culberson JC; Erb JM; Freidinger RM; Pawluczyk JM; Perlow DS; Pettibone DJ; Veber DF
    Bioorg Med Chem; 1994 Sep; 2(9):971-85. PubMed ID: 7712132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in the development of oxytocin antagonists for use in preterm labor.
    Williams PD; Bock MG; Evans BE; Freidinger RM; Pettibone DJ
    Adv Exp Med Biol; 1998; 449():473-9. PubMed ID: 10026841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: Identification, stereochemistry and initial SAR.
    Wyatt PG; Allen MJ; Borthwick AD; Davies DE; Exall AM; Hatley RJ; Irving WR; Livermore DG; Miller ND; Nerozzi F; Sollis SL; Szardenings AK
    Bioorg Med Chem Lett; 2005 May; 15(10):2579-82. PubMed ID: 15863320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
    Borthwick AD; Davies DE; Exall AM; Livermore DG; Sollis SL; Nerozzi F; Allen MJ; Perren M; Shabbir SS; Woollard PM; Wyatt PG
    J Med Chem; 2005 Nov; 48(22):6956-69. PubMed ID: 16250654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
    Chan WY; Wo NC; Cheng LL; Manning M
    J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.
    Williams PD; Clineschmidt BV; Erb JM; Freidinger RM; Guidotti MT; Lis EV; Pawluczyk JM; Pettibone DJ; Reiss DR; Veber DF
    J Med Chem; 1995 Nov; 38(23):4634-6. PubMed ID: 7473590
    [No Abstract]   [Full Text] [Related]  

  • 10. Nanomolar-affinity, non-peptide oxytocin receptor antagonists.
    Evans BE; Lundell GF; Gilbert KF; Bock MG; Rittle KE; Carroll LA; Williams PD; Pawluczyk JM; Leighton JL; Young MB
    J Med Chem; 1993 Dec; 36(25):3993-4005. PubMed ID: 8258821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.
    Borthwick AD; Davies DE; Exall AM; Hatley RJ; Hughes JA; Irving WR; Livermore DG; Sollis SL; Nerozzi F; Valko KL; Allen MJ; Perren M; Shabbir SS; Woollard PM; Price MA
    J Med Chem; 2006 Jul; 49(14):4159-70. PubMed ID: 16821776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.
    Williams PD; Anderson PS; Ball RG; Bock MG; Carroll L; Chiu SH; Clineschmidt BV; Culberson JC; Erb JM; Evans BE
    J Med Chem; 1994 Mar; 37(5):565-71. PubMed ID: 8126695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxytocin antagonists with changes in the Asn5 position shed light on hormone-oxytocin receptor interactions.
    Hill PS; Chan WY; Hruby VJ
    Int J Pept Protein Res; 1991 Jul; 38(1):32-7. PubMed ID: 1657804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo activity of the potent oxytocin antagonist on uterine activity in the rat.
    Ahn TG; Han SJ; Cho YS; An TH; Pak SC; Flouret G
    In Vivo; 2004; 18(6):763-6. PubMed ID: 15646817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors.
    Manning M; Cheng LL; Klis WA; Stoev S; Przybylski J; Bankowski K; Sawyer WH; Barberis C; Chan WY
    Adv Exp Med Biol; 1995; 395():559-83. PubMed ID: 8714021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
    Cirillo R; Gillio Tos E; Schwarz MK; Quattropani A; Scheer A; Missotten M; Dorbais J; Nichols A; Borrelli F; Giachetti C; Golzio L; Marinelli P; Thomas RJ; Chevillard C; Laurent F; Portet K; Barberis C; Chollet A
    J Pharmacol Exp Ther; 2003 Jul; 306(1):253-61. PubMed ID: 12660315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.
    Chan WY; Wo NC; Manning M
    Am J Obstet Gynecol; 1996 Nov; 175(5):1331-5. PubMed ID: 8942510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of novel bicyclic analogues derived from a potent oxytocin antagonist.
    Flouret G; Chaloin O; Borovickova L; Slaninová J
    J Pept Sci; 2006 Jun; 12(6):412-9. PubMed ID: 16432806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship investigations of a potent and selective benzodiazepine oxytocin antagonist.
    Wyatt PG; Allen MJ; Chilcott J; Hickin G; Miller ND; Woollard PM
    Bioorg Med Chem Lett; 2001 May; 11(10):1301-5. PubMed ID: 11392542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.
    Bellenie BR; Barton NP; Emmons AJ; Heer JP; Salvagno C
    Bioorg Med Chem Lett; 2009 Feb; 19(3):990-4. PubMed ID: 19095447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.